San Diego, CA, United States of America

Kate Northcote

This inventor holds 1 USPTO granted patent. Top assignee: Signal Pharmaceuticals, Inc.. Active years: 2013.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Kate Northcote

Introduction

Kate Northcote is an accomplished inventor based in San Diego, California. She has made significant contributions to the field of biotechnology, particularly in the modulation of inflammatory responses. Her work is characterized by a focus on innovative methods that have the potential to impact therapeutic approaches.

Latest Patents

Kate Northcote holds a patent for "Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines." This patent includes Aminopurine Compounds that have a specific structure, showcasing her expertise in developing novel compounds for medical applications. She has 1 patent to her name, reflecting her innovative contributions to the field.

Career Highlights

Northcote is currently associated with Signal Pharmaceuticals, Inc., where she continues to advance her research and development efforts. Her work at Signal Pharmaceuticals has positioned her as a key player in the biotechnology sector, contributing to the development of new therapeutic strategies.

Collaborations

Throughout her career, Kate has collaborated with notable colleagues, including Brydon L Bennett and Brian Edwin Cathers. These collaborations have enhanced her research and expanded the impact of her innovations.

Conclusion

Kate Northcote exemplifies the spirit of innovation in biotechnology through her patent and work at Signal Pharmaceuticals. Her contributions are paving the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…